297175-04-3Relevant academic research and scientific papers
18F-barbiturates are PET tracers with diagnostic potential in Alzheimer's disease
Calamai, Elisa,Dall'Angelo, Sergio,Koss, David,Domarkas, Juozas,McCarthy, Timothy J.,Mingarelli, Marco,Riedel, Gernot,Schweiger, Lutz F.,Welch, Andy,Platt, Bettina,Zanda, Matteo
, p. 792 - 794 (2013/02/23)
Three fluoro-barbiturates were synthesised, showing in vivo sedative efficacy. One of them, [18F]1a, was synthesised in radiofluorinated form. PET/CT Imaging with [18F]1a identified β-amyloid over-expressing transgenic mice (βA mice) compared to wild type and tau lines. The fluorescent barbiturate 9 was able to label βA plaques in brain sections of βA mice, and co-localise with a fluorescent Zn(ii) indicator.
18F-LABELLED BARBITURATE COMPOUNDS FOR USE AS POSITRON EMISSION IMAGING AGENTS
-
, (2013/03/28)
The present invention relates generally to the field of diagnostic methods. More specifically, the present invention pertains to certain 18F-labelled barbiturate compounds of the following formula (collectively referred to herein as "18F-fluorinated barbiturate compounds" and "18FBAR compounds") that bind to metals, for example, metals associated with protein aggregates, and as such are useful as imaging agents for positron emission imaging (e.g., positron emission tomography (PET) imaging) used in the diagnosis and monitoring of conditions involving these aggregates, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). These compounds also bind strongly to GABAA receptors and hence are also useful as imaging agents for positron emission tomography (PET) imaging used in the diagnosis, monitoring and study of diseases involving dis-regulation of these receptors, including epilepsy, schizophrenia, and mood disorders (e.g., anxiety).
